Clinical Trials Logo

Clinical Trial Summary

The goal of this observational study is to monitor and assess the safety profile of the MVA-BN vaccine among staff and study personnel of the PALM-007 study in the Democratic Republic of the Congo. The main questions it aims to answer are: - To estimate the incidence of serious adverse events (SAEs) in all individuals vaccinated with the MVA-BN vaccine - To estimate the incidence of adverse events (AEs) after each dose of MVA-BN vaccine. Participants will receive two doses of vaccine and will be actively followed up to the 28th day after their last dose of MVA-BN vaccine.


Clinical Trial Description

All personnel and staff of the PALM-007 study will be offered the opportunity to participate in the study by reviewing and signing the informed consent. After signing informed consent, participants will be examined. The following parameters will be assessed: - Anthropometric measurements (weight, height) - Vital signs: temperature (axillary), blood pressure, heart rate and respiratory rate - Medical history, including history of orthopox virus disease, vaccination, current co-morbidities and medication(s) - Physical examination - Pregnancy test will be done for all women of childbearing potential If a participant has met all eligibility criteria, they will be enrolled and will receive the vaccine as specified below. Participants who are excluded because of fever can be rescreened and included after resolution of the fever and its cause. Enrolled participants will receive the MVA-BN vaccine by subcutaneous injection of 0.5 mL in the shoulder (left or right). The first dose will be administered at the time of enrollment and the second dose 28 days later. After each vaccination, the participant will remain under observation for 30 minutes. All AEs occurring during this period of observation will be recorded and reported to the National Center for Pharmacovigilance and to the ethics committee according to Congolese regulations. Follow-up of participants: Participants will be followed until 28 days after the second dose of vaccine. Follow-up visit will be done either in person at National Institute of Biomedical Research (INRB) in Kinshasa and at the Monkeypox treatment centers in the PALM-007 study or by phone calls on Day 3, Day 14, and Day 28 post each vaccination. Study participants will be provided with contact information of vaccine research staff and have the right to contact the research team either directly or by phone if they have any questions about post-vaccination reactions they may be experiencing or if they are concerned. There is a window of +/- one day for each study visit except the day of the second dose which can be done on day 28 after the first dose with a window of +7 days. This second dose must not be given before Day 28. During each visit, participants will be asked to report to the research team AEs via open-ended questions. All SAEs will be followed-up. SAEs that have not resolved by the end of the per-protocol follow-up period for the subject (Day 28 after second dose) are to be followed until final outcome is known (to the degree permitted by the IRB-approved informed consent form). If it is not possible to obtain a final outcome for an SAE (e.g., the participant is lost to follow-up), the last known status and the reason a final outcome could not be obtained will be recorded by the investigator on an SAE report update and the CRF. On the day of administration of the second dose of vaccine, vital signs, and physical examination will be done to all participants and a pregnancy test will be done on all women of childbearing potential prior to vaccine administration. If the pregnancy test is positive, the second dose will not be given, and the participant will be followed up as described in the protocol. Participants will be instructed to report any AEs that are experienced outside of the protocol defined follow up days. The reporting form of the national pharmacovigilance system of the DRC will be used for reporting. The research team will complete the notification form which will be sent to the National Pharmacovigilance Center (CNPV) by e-mail (scanned copies). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05734508
Study type Interventional
Source National Institute of Allergy and Infectious Diseases (NIAID)
Contact Olivier Tshiani Mbaya, MD MTM&GH
Phone +1-240-529-4773
Email olivier.tshianimbaya@nih.gov
Status Recruiting
Phase Phase 4
Start date March 23, 2023
Completion date August 2024

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05512949 - Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine Phase 2
Completed NCT05976100 - Study of the Safety, Tolerability, Pharmacokinetics of NIOCH-14 in Volunteers Aged 18-50 Years Phase 1
Recruiting NCT05988203 - A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines Phase 1
Terminated NCT05567939 - Clinical, Virological, Immunological, Psychosocial and Epidemiological Consequences of Human Monkeypox Virus (ProMPX)
Active, not recruiting NCT05562323 - Characterization of Vaccine-induced Responses Against Monkeypox (MoVIHvax) An Observational Prospective Cohort Study
Recruiting NCT05534984 - Study of Tecovirimat for Human Monkeypox Virus Phase 3
Not yet recruiting NCT05745987 - Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster RCT Phase 4
Not yet recruiting NCT05784038 - Observational, Prospective, Cohort Study of Mpox Infection in Brazil (NETPOX)
Recruiting NCT05879965 - Prospective Study for the FOLLOW-UP of Human Monkeypox Cases and Smallpox Vaccinees at Risk
Completed NCT03745131 - Cohort Study of Healthcare Workers Receiving Imvanex®
Recruiting NCT05559099 - Tecovirimat for Treatment of Monkeypox Virus Phase 2
Completed NCT05846243 - Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 Years Phase 2/Phase 3
Not yet recruiting NCT05629299 - Pilot Study to Detect Monkey Pox Virus in Sperm: POXSPERM N/A
Recruiting NCT05654883 - New York City Observational Study of Mpox Immunity
Completed NCT05762523 - Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years Phase 1
Recruiting NCT05597735 - Assessment of the Efficacy and Safety of Tecovirimat in Patients With Monkeypox Virus Disease Phase 3
Active, not recruiting NCT05740982 - A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox Phase 2
Recruiting NCT06045923 - Virologic and Immunologic Characteristics of Severe Mpox in Persons With Advanced HIV
Recruiting NCT05947786 - Mpox Paediatric and Adolescent Clinical Study
Completed NCT05476744 - Viral Clearance and Epidemiological Characteristics in Patients With Monkeypox